UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
_______________________________
 
FORM 8-K

CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
 
SECURITIES EXCHANGE ACT OF 1934
 
 
Date of report (Date of earliest event reported):  January 24, 2011
 
Senesco Technologies, Inc.
 
(Exact Name of Registrant as Specified in Charter)

Delaware
 001-31326 84-1368850
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

303 George Street, Suite 420, New Brunswick, New Jersey 
08901
(Address of Principal Executive Offices)
(Zip Code)

(732) 296-8400
(Registrant's telephone number,
including area code)

 
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
 
 
 
 
 
Item 8.01  Other Events.

Senesco Technologies, Inc. (the “Company”) announced today that the Company has filed an Investigational New Drug application with the U.S. Food and Drug Administration for the Company’s lead drug candidate, SNS01-T, for the treatment of multiple myeloma. The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1.
 
Item 9.01.   Financial Statements and Exhibits.

(d)           Exhibits.

Exhibit No.
Description
   
99.1
Press Release of Senesco Technologies, Inc. dated
January 24, 2011.


 
 
 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
 
SENESCO TECHNOLOGIES, INC.
   
   
   
Dated: January 24, 2011
By:  /s/ Leslie J. Browne, Ph.D.
 
Name: Leslie J. Browne, Ph.D.
 
Title:   President and Chief Executive Officer